The exhaled condensate contains extracellular vesicles (EVs) with miRNA cargo of lung tissue origin that can be selectively purified and analyzed.
The purification and analysis of lung tissue-specific EVs from exhaled condensate using the EV-CATCHER assay addresses the limitations of invasive lung cancer detection methods by enabling sensitive, non-invasive miRNA profiling for early-stage lung cancer detection.
JP2026517872APending Publication Date: 2026-06-02HACKENSACK MERIDIAN HEALTH INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- HACKENSACK MERIDIAN HEALTH INC
- Filing Date
- 2024-05-10
- Publication Date
- 2026-06-02
Smart Images

Figure 2026517872000001_ABST
Abstract
This disclosure provides a non-invasive method for the early detection of deep lung lesions in subjects at risk of deep lung lesions. [Solution] This method includes (a) a step of collecting deep lung tissue from a subject at risk of deep lung lesions by isolating microRNA (riRNA) cargo of lung tissue origin within exhaled extracellular vesicles (EVs) purified from the subject's exhaled condensate (EBC); (b) a step of purifying lung-specific exhaled extracellular vesicles in the exhaled condensate by antibody capture of lung-specific exhaled EVs; and (c) a step of detecting lesions by comparing the miRNA profile of exhaled extracellular vesicles of lung tissue origin purified from the subject with the profile of exhaled extracellular vesicles purified from the exhaled condensate of a healthy subject. Early detection can lead to early treatment of lesions and improved health outcomes for the subject.
Need to check novelty before this filing date? Find Prior Art